The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Eli Lilly and Co.
Research links weight loss medications like Ozempic and Zepbound to certain serious eye conditions.
An abrupt aversion to sex is a common, albeit lesser-known, complication of taking GLP-1 medications, such as Mounjaro, ...
Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.
Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...
We recently compiled a list of the 14 Best Large Cap Dividend Growth Stocks To Buy Now. In this article, we are going to take ...
Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.
For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...
Daily Express US on MSN2d
Ozempic and Zepbound linked to rare eye conditions that could cause blindnessA new study suggests popular weight-loss drugs like Ozempic and Zepbound may be linked to rare eye conditions that could ...
A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and vision loss.
Beyond treating diabetes and helping people lose weight, GLP-1s may also improve libido. But the reasons are as complex as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback